We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Astellas Pharma Inc. (ALPMY - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Astellas Pharma Inc. is a member of the Medical sector. This group includes 997 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Astellas Pharma Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for ALPMY's full-year earnings has moved 20.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ALPMY has returned about 0.3% since the start of the calendar year. At the same time, Medical stocks have lost an average of 7.1%. As we can see, Astellas Pharma Inc. is performing better than its sector in the calendar year.
Another stock in the Medical sector, AtriCure (ATRC - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 7%.
For AtriCure, the consensus EPS estimate for the current year has increased 25.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Astellas Pharma Inc. is a member of the Medical - Drugs industry, which includes 161 individual companies and currently sits at #52 in the Zacks Industry Rank. On average, this group has lost an average of 2% so far this year, meaning that ALPMY is performing better in terms of year-to-date returns.
In contrast, AtriCure falls under the Medical - Products industry. Currently, this industry has 82 stocks and is ranked #147. Since the beginning of the year, the industry has moved +3.8%.
Investors interested in the Medical sector may want to keep a close eye on Astellas Pharma Inc. and AtriCure as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Astellas Pharma Inc. (ALPMY - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Astellas Pharma Inc. is a member of the Medical sector. This group includes 997 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Astellas Pharma Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for ALPMY's full-year earnings has moved 20.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ALPMY has returned about 0.3% since the start of the calendar year. At the same time, Medical stocks have lost an average of 7.1%. As we can see, Astellas Pharma Inc. is performing better than its sector in the calendar year.
Another stock in the Medical sector, AtriCure (ATRC - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 7%.
For AtriCure, the consensus EPS estimate for the current year has increased 25.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Astellas Pharma Inc. is a member of the Medical - Drugs industry, which includes 161 individual companies and currently sits at #52 in the Zacks Industry Rank. On average, this group has lost an average of 2% so far this year, meaning that ALPMY is performing better in terms of year-to-date returns.
In contrast, AtriCure falls under the Medical - Products industry. Currently, this industry has 82 stocks and is ranked #147. Since the beginning of the year, the industry has moved +3.8%.
Investors interested in the Medical sector may want to keep a close eye on Astellas Pharma Inc. and AtriCure as they attempt to continue their solid performance.